Lanreotide Acetate

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

17 Suppliers, 6 USDMF, 5 NDC API, 14 Listed Suppliers

DEVELOPMENTS

5 Drug(s) in Development

5 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports

DOSSIERs // Finished Dosage Forms

89 Dossiers, 6 FDA Orange Book, 44 Europe, 3 Canada, 24 Australia, 3 South Africa, 9 Listed Dossiers

DRUG PRODUCT COMPOSITION

SOLUTION;SUBCUTANEOUS - EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML), SOLUTION;SUBCUTANEOUS - EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML), SOLUTION;SUBCUTANEOUS - EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML), SOLUTION;SUBCUTANEOUS - EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML), SOLUTION;SUBCUTANEOUS - EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML), SOLUTION;SUBCUTANEOUS - EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)

GLOBAL SALES INFORMATION

8 US Medicaid Prescriptions, 16 Finished Drug Prices

MARKET PLACE

4 APIs, 5 DOSSIERS // FDF

PATENTS

3 US Exclusivities, 6 Health Canada Patents

ANALYTICAL SOLUTION(s)

3 Other Ref. Standards

3 Other Ref. Standards

DIGITAL CONTENT

1 Data Compilation & Company Tracker #PharmaFlow, 15 News

Annual Sales of Lanreotide Acetate reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Lanreotide Acetate

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

17 Suppliers

6 USDMF

5 NDC API

14 Listed Suppliers

DEVELOPMENTS

5 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

DOSSIERs // Finished Dosage Forms

89 Dossiers

6 FDA Orange Book

44 Europe

3 Canada

24 Australia

3 South Africa

9 Listed Dossiers

DRUG PRODUCT COMPOSITION

SOLUTION;SUBCUTANEOUS - EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)

SOLUTION;SUBCUTANEOUS - EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)

SOLUTION;SUBCUTANEOUS - EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)

SOLUTION;SUBCUTANEOUS - EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)

SOLUTION;SUBCUTANEOUS - EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)

SOLUTION;SUBCUTANEOUS - EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)

GLOBAL SALES INFORMATION

8 US Medicaid Prescriptions

16 Finished Drug Prices

MARKET PLACE

4 APIs

5 DOSSIERS // FDF

PATENTS

3 US Exclusivities

6 Health Canada Patents

ANALYTICAL SOLUTION(s)

3 Other Ref. Standards

DIGITAL CONTENT

1 Data Compilation & Company Tracker #PharmaFlow

15 News

Lanreotide Acetate

Ipsen

Lanreotide Acetate

Somatuline

Oncology

EURO

847

703

957

794

163

21%